Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

Alzheimer’s patients and their loved ones have new reason for hope following Phase 3 trial results of lecanemab released by Eisai Tuesday night. The results showed the drug reduced the progression of Alzheimer’s by 27 percent over 18 months, compared to placebo. Like other drugs in the same class, lecanemab is designed to slow the progression of Alzheimer’s disease by targeting amyloid plaque buildup in the brain.

Join Us at the 2022 National Alzheimer's Summit

Throughout two half-days, October 12-13, sessions will cover the latest scientific developments in prevention, early detection, and treatment—with a focus on ensuring more equitable access to innovations for everyone.

Say Hello to BrainGuide

Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

The Brain Health Academy

Free, evidence-based courses to equip healthcare and wellness providers with the knowledge and resources to help people reduce the risk of dementia and Alzheimer’s. Next Session: Physical Activity and Dementia October 19, 2022

UsAgainstAlzheimer’s Urges CMS to Reconsider Rule Limiting Access to PET Scans

UsAgainstAlzheimer’s Urges CMS to Reconsider Rule Limiting Access to PET Scans

UsAgainstAlzheimer’s chair and co-founder George Vradenburg submitted public comment to Centers for Medicare and Medicare Services (CMS) urging the agency to reconsider their National Coverage Determination (NCD) and provide coverage without CED for the FDA-approved use of amyloid-beta PET scan.

New Survey: Three in Four in Alzheimer’s Community Want Medicare to Cover Alzheimer’s Treatments

A new A-LIST® survey of people with Alzheimer’s and Alzheimer’s caregivers shows that 75 percent want Medicare to cover new therapies—even after they are told that the drugs have a risk of side effects and still require confirmatory trials.

Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

You don't want to miss this!

Say Hello to BrainGuide

The Brain Health Academy

UsAgainstAlzheimer’s Urges CMS to Reconsider Rule Limiting Access to PET Scans

Three in Four in Alzheimer’s Community Want Medicare to Cover Alzheimer’s Treatments

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is one of the most significant health and social economic crises of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • September 28, 2022

    Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

    Alzheimer’s patients and their loved ones have new reason for hope following...

    Read more
  • September 27, 2022

    Months After Denying Medicare Coverage for Alzheimer’s Drugs, CMS Announces a Premium Cut

    The Centers for Medicare and Medicaid Services (CMS) has announced it plans...

    Read more
  • Letter from Leading Alz Researchers: Journal “overstates and distorts” influence of flawed 2016 study

    In a letter to the editor published in Science responding to the...

    Read more
  • August 08, 2022

    FDA Deals Major Blow to Patients with Alzheimer’s-Related Psychosis

    Yesterday, Acadia Pharmaceuticals announced that it has been told by the FDA...

    Read more
  • A-LIST Pulse of the Community Vol 12, August 2022

    The mission of the A-LIST is to leverage data to make life...

    Read more
  • July 18, 2022

    UsAgainstAlzheimer’s Urges CMS to Reconsider Rule Limiting Access to PET Scans

    Washington, D.C. (July 15, 2022) – UsAgainstAlzheimer’s chair and co-founder George Vradenburg ...

    Read more

Reports

  • Resources
    Us Against Alzheimer's 2021 Annual Report

    2021 Annual Report

    With breakthroughs in treatment, a remarkable step forward in prevention, and a new initiative to raise public awareness of the importance of brain health, many efforts were led by UsAgainstAlzheimer’s...

  • Resources
    A-List 2017-2022 surveys

    A-List What Matters Most Surveys

    A-List 2017-2022 surveys, updated July 2022

  • Resources

    A-LIST Pulse of the Community - December 2021